-
Mashup Score: 20
We are living in exciting times for stroke therapy. The past decade has seen many novel, innovative treatments for ischemic stroke 1 and intracerebral hemorrhage (ICH). 2 Endovascular stroke treatment has revolutionized the field and is one of the most effective therapies in medicine ever. Given the importance of time is brain, recent initiatives are aimed at reducing the door-to-groin puncture time for endovascular treatment by using a one-stop approach bringing suitable patients with a suspected stroke
Source: www.ahajournals.orgCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 20
We are living in exciting times for stroke therapy. The past decade has seen many novel, innovative treatments for ischemic stroke 1 and intracerebral hemorrhage (ICH). 2 Endovascular stroke treatment has revolutionized the field and is one of the most effective therapies in medicine ever. Given the importance of time is brain, recent initiatives are aimed at reducing the door-to-groin puncture time for endovascular treatment by using a one-stop approach bringing suitable patients with a suspected stroke
Source: www.ahajournals.orgCategories: General Medicine News, NeurologyTweet-
RT @DavidSeiffge: What if your direct-to-angio patient has ICH? My Editorial in @StrokeAHA_ASA https://t.co/Ln2fGrbwdZ Is one-stop treat…
-
-
Mashup Score: 79SUMMIT MAX: A randomized trial of the super large bore HiPoint Reperfusion System versus Vecta System for aspiration thrombectomy | Stroke - 27 day(s) ago
Background: Rapid and complete recanalization is a primary goal in the endovascular treatment of large vessel occlusion stroke. The effectiveness and safety of super large bore aspiration catheters (.088” inner diameter) for the treatment of large vessel occlusion stroke have not been demonstrated in a randomized trial. Methods: SUMMIT MAX was a prospective, randomized, controlled, open label clinical trial of patients with ICA and MCA M1 occlusions, comparing the super large bore HiPoint Reperfusion system (Route 92 Medical) to the Vecta Aspiration system (Stryker Neurovascular) (NCT05018650). We hypothesized that the effectiveness and safety of the HiPoint reperfusion system was non-inferior (12.5% non-inferiority margin) to the Vecta Aspiration system. The primary effectiveness endpoint was successful reperfusion, defined as mTICI ≥ 2b as adjudicated by an independent core lab, using only the assigned study device, with any use of a non-study device prior to or following use of stud
Source: www.ahajournals.orgCategories: General Medicine News, NeurologyTweet-
SUMMIT MAX: A randomized trial of the super large bore HiPoint Reperfusion System versus Vecta System for aspiration thrombectomy | Stroke https://t.co/lij5qX3srV Presented this morning at #ESOC2025 with @gdabus @ajitspuri1 et al. in Helsinki https://t.co/FRIcFWNOJa
-
-
Mashup Score: 70SUMMIT MAX: A randomized trial of the super large bore HiPoint Reperfusion System versus Vecta System for aspiration thrombectomy | Stroke - 28 day(s) ago
Background: Rapid and complete recanalization is a primary goal in the endovascular treatment of large vessel occlusion stroke. The effectiveness and safety of super large bore aspiration catheters (.088” inner diameter) for the treatment of large vessel occlusion stroke have not been demonstrated in a randomized trial. Methods: SUMMIT MAX was a prospective, randomized, controlled, open label clinical trial of patients with ICA and MCA M1 occlusions, comparing the super large bore HiPoint Reperfusion system (Route 92 Medical) to the Vecta Aspiration system (Stryker Neurovascular) (NCT05018650). We hypothesized that the effectiveness and safety of the HiPoint reperfusion system was non-inferior (12.5% non-inferiority margin) to the Vecta Aspiration system. The primary effectiveness endpoint was successful reperfusion, defined as mTICI ≥ 2b as adjudicated by an independent core lab, using only the assigned study device, with any use of a non-study device prior to or following use of stud
Source: www.ahajournals.orgCategories: General Medicine News, NeurologyTweet-
SUMMIT MAX: A randomized trial of the super large bore HiPoint Reperfusion System versus Vecta System for aspiration thrombectomy | Stroke https://t.co/lij5qX3srV Presented this morning at #ESOC2025 with @gdabus @ajitspuri1 et al. in Helsinki https://t.co/FRIcFWNOJa
-
-
Mashup Score: 2#ISC25 - Dr. Jose Rafael Romero - Cerebral small vessel disease - 4 month(s) ago
Dr. Jose Rafael Romero, associate professor of neurology at Boston University School of Medicine, researches cerebral small vessel disease, which affects the…
Source: www.youtube.comCategories: General Medicine News, NeurologyTweet-
RT @robertaraujoc: #ISC25 - Dr. Jose Rafael Romero - Cerebral small vessel disease https://t.co/ZCsvmESk2s via @YouTube
-
-
Mashup Score: 18DISTAL Results - 4 month(s) ago
Tudor Jovin, MD interviews Urs Fischer, MD and Marios Psychogios about the results of the DISTAL trial, which compared endovascular treatment plus best medic…
Source: www.youtube.comCategories: General Medicine News, NeurologyTweet-
RT @FishingNeurons: Interview on the DISTAL trial at ISC25 https://t.co/NyddyY4NEa
-
-
Mashup Score: 19Safety of Adjunctive Intraarterial Tenecteplase Following Mechanical Thrombectomy: The ALLY Pilot Trial | Stroke - 5 month(s) ago
BACKGROUND: Recent studies suggest that the use of adjunctive intraarterial alteplase after mechanical thrombectomy (MT) may improve outcomes; however, there are limited data on the use of intraarterial tenecteplase, a newer-generation lytic, in this acute ischemic stroke patient population. Here, we evaluate the use of intraarterial tenecteplase in the ALLY pilot study (Adjunctive Intraarterial Tenecteplase Following Mechanical Thrombectomy). METHODS: ALLY was a prospective, single-center, nonrandomized pilot study assessing the feasibility and safety of intraarterial tenecteplase up to 4.5 mg in acute ischemic stroke-large vessel occlusion MT patients with incomplete recanalization. The primary safety end point was any intracranial hemorrhage and neurological worsening by ≥4 points on the National Institutes of Health Stroke Scale within 24 hours of treatment with intraarterial tenecteplase. A post hoc analysis was performed with a control cohort of MT patients (ALLY MT) not receivin
Source: www.ahajournals.orgCategories: General Medicine News, NeurologyTweet-
RT @FazalZaidi9: First US study showing safety of IA TNK for residual distal clot post MT https://t.co/QAtuZkszOj
-
-
Mashup Score: 5
The Society of Vascular and Interventional Neurology (SVIN) meeting is an annual event that brings together leading experts, researchers, practitioners and industry leaders in the field of vascular and interventional neurology.
Source: www.svin.orgCategories: General Medicine News, NeurologyTweet-
RT @almuftifawaz: 7 Days to go! https://t.co/FQpBxFcBPA @AlexandraCzap @NguyenThanhMD https://t.co/sySRkAJc4K
-
-
Mashup Score: 2Thrombectomy for Stroke With Large Infarct on Noncontrast CT - 9 month(s) ago
This clinical trial evaluates whether endovascular thrombectomy and usual medical care vs medical care alone improves functional outcomes among patients who present within 24 hours after symptom onset with anterior-circulation, large-vessel occlusion, and large infarct detected by noncontrast CT…
Source: jamanetwork.comCategories: General Medicine News, NeurologyTweet-
RT @TESLATrial: The TESLA trial @oozaidat @AlbertJYoo https://t.co/JZIO66lfOI
-
-
Mashup Score: 2Effect of Endovascular Treatment in HERMES Patients With Isolated Occlusion of the Intracranial Internal Carotid Artery - 11 month(s) ago
Background The optimal management of patients with symptomatic isolated internal carotid artery (ICA) occlusion is unknown. We aimed to assess whether endovascular treatment (EVT) compared with sta…
Source: www.ahajournals.orgCategories: General Medicine News, NeurologyTweet-
RT @SVINJournal: 2/ with moderate-to-severe deficit is safe and shows similar efficacy to EVT for ICA-L/T occlusion https://t.co/qQ2uBGcoa0
-
RT @DavidSeiffge: What if your direct-to-angio patient has ICH? My Editorial in @StrokeAHA_ASA https://t.co/Ln2fGrbwdZ Is one-stop treat…